Teva Recall

Posted on Aug 10, 2016

Teva Pharmaceuticals of North Wales, PA, has recalled seven lots of amikacin sulfate injection, USP, 500 mg/2 mL (250 mg/mL) and 1 gram/4 mL (250 mg/mL) vials because of the potential for the presence of glass particulate matter. Amikacin sulfate injection 250 mg/mL, 2 mL and 4 mL vials were distributed nationwide through wholesalers, retailers, and pharmacies. The specific lot numbers, expiration dates, and national drug code numbers can be found in the recall alert posted to FDA’s website. To date, Teva has not received any reports of adverse events or complaints related to this recall. Anyone with an existing inventory of the recalled lots should stop use and distribution and quarantine the product immediately. Adverse events or quality issues can be reported to FDA’s MedWatch Safety Information and Adverse Event Reporting Program